Palvella Therapeutics, Inc. Common Stock
Follow $PVLA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $PVLA by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredsnapshot unavailable for PVLA. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is PVLA moving today?
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
PVLA overview
Related filings and maps
Congress activity in PVLA
No receipt-qualified Congressional disclosure is present for PVLA in the cached public ledger.
PVLA contract awards, year to date.
Public federal awards linked to this ticker.
PVLA lobbying filings, year to date.
Registered lobbying filings matched to Palvella Therapeutics, Inc. Common Stock.